Laboratorios Farmaceuticos Rovi S.A (0ILL)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 62.00 |
|---|---|
| 52-week range | 52.45 – 87.50 |
| Return, 1 month / 3 months | +4.6% / +4.4% |
| Return, 1 year / 3 years | −1.7% / +30.6% |
| Trend | Below its 200-day average |
| RSI (14) | 68 |
| Volatility (1 year) | 28.6% |
| Worst drawdown (1 year) | -37.0% |
| Average daily value traded | 0.43M EUR |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Laboratorios Farmaceuticos Rovi is a Spanish pharmaceutical company based in Madrid. It develops and makes prescription medicines, with a focus on heparin-based anticoagulants and other injectable products, and it also produces and packages injectables for other drug companies under contract. Its customers are hospitals, healthcare providers and pharmaceutical partners, mainly in Europe and other international markets. The company handles its own branded medicines as well as manufacturing work for third parties.
The shares are listed on the London Stock Exchange in UK under the code 0ILL, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Laboratorios Farmaceuticos Rovi S.A (0ILL) trades on the London Stock Exchange in UK. It last closed at EUR 62.00 on 27 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 2,640 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.7% and over the last three months it rose 4.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.5% | ||
| From 52-week high | -27.9% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 4.4% | ||
| 6-month return | -22.1% | ||
| 12-month return, skipping the last month | -6.0% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.0% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.43M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.7% |
|---|---|
| 1 month | +4.6% |
| 3 months | +4.4% |
| 6 months | −22.1% |
| 1 year | −1.7% |
| 3 years | +30.6% |
| 5 years | +12.1% |
Signals
| 50-day / 200-day average | 59.05 / 65.63 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.25 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Jul 2026 | EUR 0.7771 |
| 14 Jul 2025 | EUR 0.7574 |
| 8 Jul 2024 | EUR 0.8940 |
| 3 Jul 2023 | EUR 1.0480 |
| 5 Jul 2022 | EUR 0.7740 |
| 5 Jul 2021 | EUR 0.3088 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.